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Abstract
 
Allergic asthmatic responses in the airway are associated with airway hyperreactivity, eosino-
phil accumulation in the lung, and cytokine production by allergen-specific, T helper cell type
2 (Th2) lymphocytes. Here, we show that in a cockroach antigen (CA) model of allergic pul-
 
monary inflammation, the chemokine macrophage inflammatory protein (MIP)-3
 
 
 
 is ex-
pressed in the lung within hours of allergen challenge. To determine the biologic relevance of
this expression, mice lacking CCR6, the only known receptor for MIP-3
 
 
 
, were studied for
their response to CA. CCR6-deficient mice were immunized to the same extent as their wild-
type counterparts, as judged by cytokine production in antigen-challenged lymphocytes.
However, compared with CA-challenged wild-type mice, challenged CCR6-deficient mice
had reduced airway resistance, fewer eosinophils around the airway, lower levels of interleukin
5 in the lung, and reduced serum levels of immunoglobulin E. Together, these data demon-
strate that MIP-3
 
 
 
 and CCR6 function in allergic pulmonary responses and suggest that these
molecules might represent novel therapeutic targets for treatment of asthma.
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Introduction
 
Asthma is a chronic disease of the lung, characterized clini-
cally by a reversible obstruction in airflow resulting from
edema, mucus production, and hyperresponsiveness of the
bronchi. Millions of people are affected by this disease, and
its incidence is increasing, particularly in developed na-
tions. Asthmatic responses to inhaled allergens are associ-
ated with IgE-mediated mast cell activation followed by
the accumulation of leukocytes (1–3), especially eosinophils
(1, 4), in and around the affected airway. Th2 lymphocytes,
which are defined by their production of the proinflamma-
tory cytokines IL-4, IL-5, and IL-13, have also been linked
to the asthmatic condition and to the recruitment and acti-
vation of eosinophils (2, 5–9). Thus, Th2 lymphocytes and
eosinophils are key effector cells of asthmatic responses.
CCR6 is a chemokine receptor that is expressed in im-
mature dendritic cells (DCs) (10–12) as well as in B lym-
phocytes (13, 14) and memory T cells (13). The only
known chemokine ligand for CCR6 is macrophage in-
flammatory protein (MIP)-3
 
 
 
 (CCL20), although mem-
bers of the 
 
 
 
 defensin family also bind CCR6 with a lower
affinity (15). MIP-3
 
 
 
 is constitutively expressed in the
spleen and in the epithelium overlying the subepithelial
 
dome (SED) of murine Peyer’s patches (16, 17) and hu-
man tonsils (18). In gene-targeted mice lacking CCR6
 
(CCR6
 
 
 
/
 
 
 
 mice), myeloid DCs are either absent or very
underrepresented in the SED compared with wild-type
mice (17). In addition, CCR6
 
 
 
/
 
 
 
 mice have impaired mu-
cosal immune responses to oral immunization with KLH
and to enterovirus challenge.
 
Like the intestine, the airway is also covered with a mu-
cosal surface that contacts inhaled allergens, suggesting that
 
MIP-3
 
 
 
 and CCR6 might also participate in the mucosal
immune response to inhaled antigens. However, unlike
the Peyer’s patch, the lungs and lymph nodes of unchal-
lenged mice do not constitutively express MIP-3
 
  
 
(16,
17), although its expression has been reported in lymph
nodes during inflammatory conditions (12, 16). To deter-
mine whether MIP-3
 
 
 
 and CCR6 participate in pulmo-
nary allergic responses, we studied the response of
 
CCR6
 
 
 
/
 
  
 
mice to cockroach antigen (CA). The dimin-
ished allergic responses seen in CCR6
 
 
 
/
 
 
 
 mice support a
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Reduced Allergic Responses in CCR6
 
   
 
 Mice
 
role for CCR6 in allergic pulmonary inflammation and in
Th2 immunity.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice were purchased from The Jackson Lab-
oratory. CCR6
 
 
 
/
 
 
 
 mice were obtained as described previously
and subsequently backcrossed for eight generations onto the
C57BL/6 background.
 
CA Challenge.
 
C57BL/6 mice were immunized with 10 
 
 
 
g
of CA (Bayer Pharmaceuticals) in incomplete Freund’s adjuvant
as described previously (19). For cytokine analysis, mice were
challenged once with allergen on day 14. For airway hyperreac-
tivity assessment, mice were challenged a second time, 48 h after
primary challenge. For cytokine analysis of lymph node cells, an-
imals were given a single intratracheal challenge, and the draining
thoracic lymph nodes were harvested after 48 h. The single-cell
suspension of lymph node cells was then restimulated in vitro
with 5 
 
 
 
g of CA. Supernatants and cells were harvested for cy-
tokine mRNA (Taqman) and protein (ELISA) analysis.
 
Measurement of Airway Hyperreactivity.
 
Airway hyperreactiv-
ity in anesthetized mice was measured as described previously
(20) with a mouse plethysmograph (Buxco) using a direct ventila-
tion method specifically designed for low tidal volumes.
 
RNA Isolation and Analysis.
 
Lungs were harvested at various
times after challenge, and RNA was prepared from them using
RNA-STAT 60 reagent (Tel-Test, Inc.) according to the manu-
facturer’s specifications. Complementary (c)DNA was prepared
from individual lungs using the Superscript RT kit (Life Technol-
ogies) with the addition of random sequence hexamers (Promega)
to 10 ng/
 
 
 
l. cDNA was analyzed by quantitative, real-time PCR
using a Taqman 7700 instrument (Applied Biosystems). Taqman
PCR reactions consisted of 25 ng of cDNA, 0.9 
 
 
 
M each diag-
nostic primer, 0.25 
 
 
 
M diagnostic probe, 1
 
 
 
 final of rRNA
PDAR (predeveloped assay reagent) (Applied Biosystems), and 1
 
 
 
final of Taqman Universal PCR Mastermix (Applied Biosystems).
The default 7700 thermocycler parameters were used. Spectral
data from Taqman runs were analyzed using the Sequence Detec-
tion Systems software (version 1.6.3; Applied Biosystems). Raw
data were normalized to the rRNA internal control standards.
 
ELISAs.
 
Whole lungs were homogenized in 1 ml of high
salt lysis buffer containing protease inhibitors. Debris-free super-
natants were isolated and the cytokines measured by ELISA as
described (21). Antibody pairs from R & D Systems were used
for IL-5 and IL-4 analysis, and polyclonal antibodies made in our
University of Michigan laboratory were used in the IL-13
ELISA. The sensitivity of the analyses was 
 
 
 
10 pg/ml. No cross-
reactivity to any other chemokine or cytokine was detected.
 
Statistics.
 
Statistical significance was determined by ANOVA.
 
P
 
 
 
 
 
 0.05 was considered significant.
 
Results and Discussion
 
MIP-3
 
 
 
 Is Induced by Allergen Challenge.
 
We first inves-
tigated whether MIP-3
 
 
 
 is expressed in the lungs of wild-
type C57BL/6 mice after sensitization and challenge with
CA. This allergen was used because of its clinical relevance
and because it induces responses typical of asthma, includ-
ing production of Th2 cytokines, eosinophil infiltration,
and airway hyperreactivity. Quantitative PCR analysis
(Taqman) was performed on cDNAs derived from total
 
lung RNA. In sensitized but unchallenged mice, only very
low levels of MIP-3
 
 
 
–specific mRNA were detected.
However, shortly after CA challenge, these levels increased
dramatically, peaking at 8 h after challenge (Fig. 1). These
data show that MIP-3
 
 
 
, the only known chemokine ligand
for CCR6, is expressed in allergen-challenged lungs.
 
CCR6
 
 
 
/
 
 
 
 Mice Have Reduced Airway Hyperreactivity after
CA Challenge.
 
To investigate whether the induction of
MIP-3
 
 
 
 in lungs and lymph nodes was of functional impor-
tance in pulmonary allergic responses, we investigated the
physiologic response of CCR6
 
 
 
/
 
 
 
 mice to CA challenge.
As airway hyperreactivity is the feature considered most rel-
evant to human asthma, we measured this parameter in the
lungs of both wild-type and CCR6
 
 
 
/
 
 
 
 mice. In both sets of
mice, airway resistance peaked at 
 
 
 
8 h after challenge.
However, the resistance in CCR6
 
 
 
/
 
 
 
 mice was two- to
threefold lower than that seen in wild-type mice (Fig. 2).
24 h after challenge, the resistance in both groups had de-
clined from that seen at 8 h, but in CCR6
 
 
 
/
 
 
 
 mice it re-
mained significantly lower than in wild-type controls. Sim-
ilarly, 48 h after challenge, resistance in CCR6
 
 
 
/
 
 
 
 mice was
lower than in wild-type mice, although the difference at
this last time point did not reach statistical significance.
 
CCR6
 
 
 
/
 
 
 
 Mice Have Reduced Peribronchial Eosinophil Ac-
cumulation.
 
Previous studies have demonstrated that air-
way hyperreactivity after multiple allergen challenges is
closely associated with the level of peribronchial eosino-
phil accumulation (19). To determine whether the inter-
action of MIP-3
 
 
 
 and CCR6 is required for the eosino-
philic response to CA, lung sections were prepared and
eosinophils counted with high-power microscopy. This
analysis revealed that CA-challenged CCR6
 
 
 
/
 
 
 
 mice had
10-fold fewer peribronchial eosinophils than challenged
wild-type mice (Fig. 3). One possible explanation for this
decrease is that MIP-3
 
 
 
 directly mediates eosinophil re-
cruitment. This hypothesis is supported by the observation
that in humans, MIP-3
 
 
 
 can directly induce eosinophil
migration (22). However, in our experiments, eosinophils
harvested from IL-5–overexpressing transgenic mice did
Figure 1. MIP-3  expression in allergen-challenged lungs. RNA was
prepared from lungs harvested at the indicated times after challenge with
CA. cDNA prepared from this RNA was used in a quantitative PCR
(Taqman) assay. Values shown represent femtograms of MIP-3  cDNA
per 25 ng total cDNA. 
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not migrate in response to murine MIP-3
 
 
 
 under condi-
tions in which murine eotaxin did induce migration (un-
published observation).
 
Analysis of Pulmonary Cytokines.
 
One possible explana-
tion for the decreased eosinophil recruitment into the air-
way of CCR6
 
 
 
/
 
 
 
 mice is that their immune response, in
particular their Th2 type immune response, is impaired.
Previous experiments using blocking antibodies and gene-
disrupted mice have shown that the Th2-associated cyto-
kines IL-4, IL-5, and IL-13 function to maintain a proasth-
matic environment in animal models of asthma (7, 23, 24).
IL-4 can initiate IgE isotype switching and may induce se-
lective vascular cell adhesion molecule 1 expression, IL-5 is
important for eosinophil maturation and enhances accumu-
lation in the lung, and IL-13 functions together with IL-4
to induce mucous production (8, 9). To determine
whether the levels of these important cytokines are affected
by the absence of CCR6, we performed ELISAs on lung
 
homogenates of challenged mice. A five- to eightfold de-
crease in IL-5 levels was seen in CCR6
 
 
 
/
 
 
 
 compared with
wild-type mice (Fig. 4), suggesting that the reduced num-
ber of eosinophils in lungs of the CCR6
 
 
 
/
 
 
 
 mice might be
due to decreased IL-5 production. Interestingly, levels of
IL-4 and IL-13 were not significantly reduced in CCR6
 
 
 
/
 
 
 
mice compared with wild-type mice (data not shown).
Thus, IL-5 but not other Th2 cytokines are reduced in the
chronic phase of CA-challenged CCR6
 
 
 
/
 
 
 
 mice.
 
IgE Production.
 
Another hallmark of the asthmatic re-
sponse is an increase in circulating levels of IgE. To deter-
mine whether the reduced IL-5 and airway hyperreactivity
seen in the CCR6
 
 
 
/
 
 
 
 mice was also associated with di-
minished IgE production, serum levels of this antibody iso-
type were assessed. This analysis revealed that CCR6
 
 
 
/
 
 
 
mice had considerably lower levels of IgE than wild-type
mice (Fig. 5). This finding is consistent with previous re-
sults demonstrating an association between levels of IL-5
and IgE (25).
 
Immunization.
 
To address the possibility that the re-
duced response in the lungs of CCR6
 
 
 
/
 
  
 
mice was related
to a reduced capacity to be immunized, we prepared lym-
phocyte cultures from the lymph nodes of CA-immunized
mice and measured cytokine production after CA stimula-
Figure 2. Lung function in CA-challenged mice. After intratracheal
challenge with CA (10  g), mice were ventilated and administered meth-
acholine (100  g/kg) intravenously. Values shown represent the change
in airway resistance (cm/H2O/ml/s), defined as peak airway resistance
minus the background resistance. Mean values   SE are shown. n   5
animals per treatment group. *P   0.05.
Figure 3. Peribronchial eosinophil accumulation in CCR6 /  mice.
Morphometric enumeration of eosinophils was performed in a blinded
fashion on five to six mice in each group. Lungs were harvested 24 h after
challenge, processed, and sectioned. Bronchi-associated eosinophils were
counted for 100 high-power fields (HPF). P   0.05.
Figure 4. Pulmonary IL-5 levels in CCR6 /  mice. Whole lungs were
harvested 24 h after challenge and examined for IL-5 protein by ELISA.
Values shown represent the mean   SEM of three separate experiments
with six mice in each group. P   0.05.
Figure 5. Serum IgE. Total IgE levels were measured in serum pre-
pared from normal and allergic wild-type and CCR6 /  mice. IgE in
unsensitized animals was below the limit of detection. Values shown rep-
resent the means   SEM of six mice per group. P   0.05.554 Reduced Allergic Responses in CCR6    Mice
tion in vitro. Compared with lymphocytes prepared from
nonimmunized mice, large increases in IL-4 production
were seen in both challenged wild-type (590   11-fold)
and challenged CCR6 /  mice (481   7-fold). Similarly,
IL-5 was increased in wild-type (6.2    0.4-fold) and
CCR6 /  mice (6.1   0.2-fold). Thus, the extent of im-
munization was comparable in the two groups of chal-
lenged mice.
Taken together, the data from these studies support a
role for CCR6 in allergic airway responses. In particular,
CCR6 is required for normal allergen-induced eosinophil
accumulation and for production of IL-5 and IgE. This
blunted response in the lung mucosa is consistent with the
diminished humoral response previously seen in the intesti-
nal mucosa of CCR6 /  mice and suggests that CCR6
might have a general function in mucosal immune re-
sponses. The expression of CCR6 in DCs, memory T cells,
and B lymphocytes suggests that the diminished allergic re-
sponse in CCR6 /  mice might result from impaired func-
tion of one or more of these cell types. Thus, although the
mechanism of CCR6 action in this model remains unclear,
the data presented here identify CCR6 as a potential thera-
peutic target for individuals suffering from pathophysio-
logic responses to airway allergens.
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